Feb 20, 2024 8:30am EST Veru Announces New Scientific Advisory Board for its Enobosarm Program for High Quality Weight Loss
Feb 06, 2024 8:30am EST Veru Announces FDA Clearance of IND Application to Initiate Phase 2b Clinical Trial with Enobosarm to Treat Muscle Loss Associated with Weight Loss Drugs
Jan 31, 2024 8:30am EST Veru to Present at the Oppenheimer 34th Annual Healthcare Life Sciences Conference
Jan 25, 2024 8:30am EST Veru to Report Fiscal 2024 First Quarter Financial Results on February 8, 2024
Jan 08, 2024 8:30am EST Veru Submits IND Application to FDA for the Development of Enobosarm to Prevent Muscle Loss While Augmenting Fat Loss in Combination with GLP-1 Drugs for Weight Loss
Dec 19, 2023 8:30am EST Veru to Host Investor Call on January 4th, 2024 to Discuss Recent Financing and Strategy to Prioritize the Development of Enobosarm as a Combination Treatment to Prevent Muscle Loss and Augment Fat Loss Associated with Weight Loss GLP-1 Drugs
Oct 04, 2023 8:30am EDT Veru Reports Muscle Data from 5 Clinical Studies of Enobosarm that Support the Advancement of Enobosarm in Combination with Weight-Loss GLP-1 Drugs, Ozempic®, Wegovy®, or Mounjaro®, to Optimize Weight Loss by Preventing Muscle Wasting and Further Increasing Fat Loss in a Phase 2b Obesity Clinical Study
